文学城投坛最近流行千万梦，俺博士后挣得少，还不能冒险，能不能也有一个千万梦呢？
昨天老板把试验室的人召集起来，先让学校的摄影师拍好照，作press release的准备；再给我们开了个小会，说找好了律师，要正式办一个皮包公司了。虽然专利能不能拿到还不知道，但公司的运作还是要的。老板从没办过公司，都是律师指示作什么，他就照办：先分配专利的所有权。俺居然拿到了4.5%的share。。。
他鼓励大家：不要说我们作的东西没有钱途。最近的例子就是针对抗药性前列腺癌的药物，也是一个大学教授搞出来的，后来自己办公司，临床试验等等等，最后卖了1.2B。而那个教授这次是杂志特约审我们文章的。。。
希望借他的仙气，卖个250M,我不就千万级了么。
哈哈，博士后也可以有梦么。从今天开始，米不用数了，数千万。：）））。
（二0一五年三月二十日）
这就是生物人的梦（ZT)：
ARN-509, A Next Generation Anti-Androgen: From Discovery to Clinical Development
Richard Heyman, PhD，Aragon Pharmaceuticals
October 26, 2012—Castration-resistant prostate cancer (CRPC) is defined by tumor growth, even with lowered blood levels of testosterone, which is a male androgen hormone. This form of prostate cancer is marked by resistance to drugs—such as leuprolide, gosereline or casodex—that either lower the amount of testosterone in the blood or the persistence of the androgen receptor (AR) signaling. (Androgens can fuel prostate cancer progression; AR binds to testosterone in the cytoplasm and ushers it into the cell’s nucleus, allowing it to give “instructions” that trigger changes in transcriptional signaling that drive tumor proliferation. Currently there are several anti-androgen drugs on the market to treat advanced prostate cancer. By definition, anti-androgen drugs bind to the AR protein and block its function.
A novel second-generation anti-androgen drug, ARN-509, was discovered by PCF-funded researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and UCLA and the compound has recently entered Phase II clinical trials being conducted MSKCC and 13 others across the U.S.
Aragon Pharmaceuticals, based in San Diego, has licensed the ARN-509 and is conducting the studies in men with CRPC to determine safety, tolerability and anti-tumor activity of the drug. Preclinical data show that this second-generation anti-androgen, ARN-509 is more efficacious in models of CRPC, thus making it a potentially more effective anti-androgen drug than first-generation compounds. Early results from the Phase I portion of the study showed that about half of patients receiving ARN-509 experienced PSA declines of 50 percent or greater during the trial period.
During a discussion at the 19th Annual PCF Scientific Retreat Dr. Richard Heyman of Aragon discussed the preclinical work in rodents—e.g., robust tumor regression in CRPC mousemodels and low brain tissue exposure and better results compared to a standard drug used to treat CRPC—that led to the human clinical trials now underway.
He spoke of the excellent safety profile seen to date in Phase I clinical trials and the establishment of the recommended Phase II dose. In addition, PET imaging of men with CRPC receiving ARN-509 demonstrates robust AR blockade after four weeks of treatment.
To date, approximately 100 men are enrolled in the Phase II study with robust PSA responses in three individual cohorts of the CRPC patients. The drug at the established recommended dose continues to be well-tolerated. During the Q & A session that followed the presentation, Dr. Heyman was asked if they would be doing trials of ARN-509 in comparison to Xtandi (also a 2nd generation anti-androgen) in the future; he responded that his company is exploring all the options.
PCF Funding: Charles Sawyers, One of the key scientists behind the discovery of ARN-509 has received major PCF funding over the span of many years.
